Calcimedica, Inc. annual report, FY2021

完整文档

Issuer and reporting period

Important issuer mismatch: The supplied filing is Graybug Vision, Inc. (Nasdaq: GRAY), not CalciMedica, Inc. It is a Form 10-K for the fiscal year ended December 31, 2021, filed March 10, 2022—not a standalone fourth-quarter report. The summary below covers Graybug’s filing.

Graybug is a clinical-stage ophthalmology biopharmaceutical company with no approved products or product revenue. Its lead candidate, GB-102, is a sustained-release sunitinib injection being developed primarily for wet age-related macular degeneration (AMD); GB-401 is an investigational glaucoma implant.

Financial performance and position

  • Revenue: No product sales; the filing reports no revenue-generating activities.
  • Net loss: $35.8 million in 2021, versus $27.5 million in 2020. Basic and diluted loss per share was $1.69, versus $5.25 in 2020; the prior-year per-share result included preferred-stock dividends and a substantially smaller weighted-average share count.
  • Operating expenses: $35.9 million, up 20% from $29.8 million. Research and development fell 10% to $18.9 million, mainly due to completion of the GB-102 Phase 2b treatment phase. General and administrative expense rose 92% to $17.0 million.
  • Unusual expense items: General and administrative expense included a $1.35 million write-off of equipment-purchase deposits. The company also reported $2.2 million of expense associated with terminated equipment-vendor and manufacturing commitments, including the deposit write-off and cancellation costs.
  • Cash flow: Operating activities used $31.5 million, compared with $32.1 million in 2020. Investing activities provided $10.8 million, largely reflecting investment maturities and purchases; financing activities provided $0.7 million, primarily from option exercises. The 2020 financing inflow included IPO proceeds.
  • Liquidity: Cash, cash equivalents and short-term investments totaled $63.7 million at year-end, down from $95.0 million at the end of 2020. Current assets were $67.1 million and current liabilities $4.1 million. Management stated the resources were expected to fund operations into the second half of 2023 under its then-current plan; it also said additional financing would be sought.
  • Debt and obligations: The filing does not report outstanding borrowings or a credit facility. It disclosed $732,000 of future lease payments and approximately $0.8 million of other commitments due within 3 to 15 months. Potential development and regulatory milestone payments under acquired licenses are contingent, not recorded as liabilities when achievement was not considered probable.
  • Profitability and margins: Not meaningful because the company had no product revenue and reported operating losses.

Material changes and business developments

  • ALTISSIMO, the controlled Phase 2b wet-AMD study, enrolled 56 patients; 50 completed the 12-month core study. In the intended 1 mg dosing group, 10 of 21 patients (48%) went at least six months without additional anti-VEGF treatment. Among the 11 in that group who entered the extension, 6 (55%) reached Month 18 without rescue treatment.
  • GB-102’s mean visual-acuity results trended below the aflibercept control; the filing cites an approximately 9-letter lower mean BCVA across time points for the 1 mg dose in Phase 2b. The trial was not powered to establish statistical efficacy. The company said CST control was similar to aflibercept, but this does not resolve the visual-acuity concern.
  • Graybug discontinued the 2 mg GB-102 dose after safety findings that included medication in the anterior chamber and two serious ocular events in one patient in a separate macular-edema study. It planned to test a reformulated diluent intended to reduce particle dispersion.
  • Research and development spending declined while G&A increased, including higher stock-based compensation and directors’ and officers’ insurance costs following the 2020 IPO.
  • In December 2021, Graybug acquired intellectual-property rights to cGMP compounds for ocular disorders for $0.5 million upfront, with up to $27 million in potential milestone payments and tiered single-digit royalties. A separate gene-therapy acquisition occurred in March 2022, after the reporting date.

Outlook, risks and contingencies

  • Graybug planned an additional open-label Phase 2 wet-AMD study of GB-102 using the reformulated diluent, subject to FDA feedback; it anticipated an IND amendment in the second half of 2022. Further Phase 3 development was contingent on obtaining a development partner to fund some or all of the work.
  • The company expected to submit an IND and begin a GB-401 Phase 1/2a glaucoma study in the first half of 2023. These are forward-looking plans, not assured milestones.
  • Management expected 2022 R&D expense to increase from 2021. It did not provide revenue or earnings guidance and emphasized that cash runway estimates depend on assumptions and the current development plan.
  • Key risks include clinical efficacy and safety uncertainty, particle dispersion, the need for a GB-102 partner, additional financing needs and potential dilution, competition, regulatory delays, reliance on contract manufacturers, reimbursement uncertainty, and possible COVID-19-related disruption. The company noted that GB-102 uses sunitinib, which carries a boxed hepatotoxicity warning for its oncology uses, although systemic sunitinib was not detected in its reported ocular studies.
  • No legal proceedings were reported that management believed would have a material adverse effect. The independent auditor issued an unqualified opinion on the financial statements; management reported effective disclosure controls and internal control over financial reporting. The auditor did not attest to internal control, consistent with the company’s emerging-growth-company exemption.

Most important facts for investors to verify

  1. Confirm the intended issuer: the provided document is Graybug Vision’s 2021 Form 10-K, not a CalciMedica filing.
  2. Review the complete ALTISSIMO efficacy and safety data, especially the visual-acuity difference versus aflibercept and the small patient counts.
  3. Check whether FDA feedback, the reformulated GB-102 study, and a funding or licensing partner were subsequently obtained.
  4. Assess actual cash burn, financing raised, and updated runway against the filing’s conditional second-half-2023 estimate.
  5. Review subsequent progress and costs for GB-401 and the acquired programs, including contingent milestones and potential dilution.